A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy

PURPOSE: Classification and treatment of WHO grade II/III gliomas have dramatically changed. Implementing molecular markers into the WHO classification raised discussions about the significance of grading and clinical trials showed overall survival (OS) benefits for combined radiochemotherapy. As mo...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Cancer Res Clin Oncol
Prif Awduron: Steidl, Eike, Filipski, Katharina, Zeiner, Pia S., Wagner, Marlies, Fokas, Emmanouil, Forster, Marie-Therese, Ronellenfitsch, Michael W., Divé, Iris, Steinbach, Joachim P., Harter, Patrick N., Bähr, Oliver
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Berlin Heidelberg 2021
Pynciau:
Original Article – Clinical Oncology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8236451/
https://ncbi.nlm.nih.gov/pubmed/33538917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-021-03511-y
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg